Fundraising FoxOnKure, Inc.
Boulder, US · Delaware corporation · 7 known investors
Find your way into OnKure, Inc.
Sign up to find every way you can get introduced to OnKure, Inc.
- Your email: who you already know at OnKure, Inc., and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the OnKure, Inc. team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Engaged in discovery and development of targeted small molecule therapies for cancer treatment, including selective mutant-specific PI3K inhibitors.
Founders & leadership
AD
Anthony D. PiscopioFounder
NS
Nicholas SaccomanoExecutive
DW
Duncan WalkerExecutive
JW
James WinklerExecutive
JL
Jason LeveroneExecutive
Board
IM
RM
R. Michael CarruthersBoard director
AJ
Andrew J. PhillipsBoard director
Investors · 7
Samsara BioCapitallisted by Samsara BioCapitalMenlo Park
How we know: Samsara BioCapital's portfolio page · funding news · globenewswire.com · Not right? Tell us
ACORN BIOVENTURESreportedNew Yorkvia Isaac Manke · board
How we know: board seat on SEC Form D · funding news · globenewswire.com · Not right? Tell us
BlackRockreportedNew York
How we know: globenewswire.com · Not right? Tell us
Also in the syndicate · 4
Cormorant Asset ManagementDeep Track CapitalPerceptive AdvisorsSurveyor Capital (a Citadel company)lead
Reported raises · per SEC filings
Form D private placements$122.1M disclosed across 8 rounds · 2015–2023
▶$53.8MraisedApr 2023 · 15 investors · PharmaceuticalsRule 506(b)
▶$53.8MraisedApr 2023 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Anthony D. PiscopioExecutive Officer, Director
- R. Michael CarruthersDirector
- Andrew J. PhillipsDirector
- Isaac MankeDirector
- Nicholas SaccomanoDirector
- Duncan WalkerExecutive Officer
- James WinklerExecutive Officer
- Jason LeveroneExecutive Officer
- Keith M. OliviaExecutive Officer
- Offering amount
- $60M
- Amount sold
- $53.8M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$56.6MraisedMar 2022 · 11 investors · PharmaceuticalsRule 506(b)
▶$56.6MraisedMar 2022 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James WinklerExecutive Officer
- Duncan WalkerExecutive Officer
- Guobao ZhaoDirector
- Nicholas SaccomanoDirector
- Keith M. OliviaExecutive Officer
- R. Michael CarruthersDirector
- John DeMatteiExecutive Officer
- Andrew J. PhillipsDirector
- Isaac MankeDirector
- Jason LeveroneExecutive Officer
- Anthony D. PiscopioExecutive Officer, Director
- Offering amount
- $56.6M
- Amount sold
- $56.6M
- Minimum investment
- $106K
- Sales commissions
- $2.8M
- Proceeds to insiders
- $5.5M
- Placement agents
- Solebury Capital LLC
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedSep 2020 · 2 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedSep 2020 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Xuedong LiuExecutive Officer, Director
- Keith Michael OliviaExecutive Officer
- Anthony D. PiscopioExecutive Officer, Director
- Donna PeakDirector
- Zhao GuobaoDirector
- John DeMatteiExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1.5M
- Minimum investment
- $100K
- Proceeds to insiders
- $120K
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.2MraisedApr 2020 · 6 investors · PharmaceuticalsRule 506(b)
▶$3.2MraisedApr 2020 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Keith Michael OliviaExecutive Officer
- Donna PeakDirector
- Xuedong LiuExecutive Officer, Director
- Anthony D. PiscopioExecutive Officer, Director
- Zhao GuobaoDirector
- John DeMatteiExecutive Officer
- Offering amount
- $5.2M
- Amount sold
- $3.2M
- Minimum investment
- $12.1K
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedMar 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$1MraisedMar 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Donna PeakDirector
- Anthony D. PiscopioExecutive Officer, Director
- Xuedong LiuExecutive Officer, Director
- John DeMatteiExecutive Officer
- Zhao GuobaoDirector
- Keith Michael OliviaExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1M
- Minimum investment
- $100K
- Proceeds to insiders
- $170.5K
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100KraisedSep 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$100KraisedSep 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Anthony D. PiscopioExecutive Officer, Director
- Donna PeakDirector
- Zhao GuabaoDirector
- Keith Michael OliviaExecutive Officer
- John DeMatteiExecutive Officer
- Xuedong LiuExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $100K
- Minimum investment
- $100K
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedFeb 2018 · 16 investors · BiotechnologyRule 506(b)
▶$5MraisedFeb 2018 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony D. PiscopioExecutive Officer, Director
- Joseph RomanoDirector
- Xuedong LiuExecutive Officer, Director
- Zhao GuabaoDirector
- Donna PeakExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $5M
- Minimum investment
- $22.5K
- Proceeds to insiders
- $525K
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$855KraisedJun 2017 · 8 investors · BiotechnologyRule 506(b)
▶$855KraisedJun 2017 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Xuedong LiuExecutive Officer, Director
- Anthony D. PiscopioExecutive Officer, Director
- Donna PeakExecutive Officer, Director
- Joseph RomanoDirector
- Offering amount
- $1M
- Amount sold
- $855K
- Minimum investment
- $20K
- Proceeds to insiders
- $20K
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does OnKure, Inc. do?
- Engaged in discovery and development of targeted small molecule therapies for cancer treatment, including selective mutant-specific PI3K inhibitors.
- Who founded OnKure, Inc.?
- OnKure, Inc. was founded by Anthony D. Piscopio.
- Who are OnKure, Inc.'s investors?
- OnKure, Inc.'s investors include Samsara BioCapital, ACORN BIOVENTURES, BlackRock.
- How much funding has OnKure, Inc. raised?
- OnKure, Inc. has disclosed $122.1M raised across 8 rounds.
- Where is OnKure, Inc. headquartered?
- OnKure, Inc. is headquartered in Boulder, US.